Interacciones de Budesonida y formoterol

At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (etiqueta de Abiraterona, Advertencias y precauciones)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Adalimumab, Advertencia en recuadro)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Inhaled beta agonist: salmeterol ↑ salmeterol Coadministration of salmeterol with REYATAZ is not recommended. (etiqueta de Atazanavir, Interacciones medicamentosas)

Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (etiqueta de Axitinib, Advertencias y precauciones)

…intubation (endotracheal) 1 2 Asthma-related hospitalization (≥24-hour stay) 115 105 ICS = Inhaled Corticosteroid, LABA = Long-acting Beta2-adrenergic Agonist The pediatric safety trial included 6208 pediatric patients 4 to 11 years of age who received ICS/LABA (fluticasone propionate /salmeterol inhalation powder) or ICS (fluticasone propionate inhalation powder). (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Baricitinib, Advertencia en recuadro)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Paradoxical Bronchospasm and Upper Airway Symptoms As with other inhaled medications, budesonide and formoterol fumarate dihydrate can produce paradoxical bronchospasm, which may be life threatening. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Known Hypersensitivity or Idiosyncrasy to the Sympathomimetic Amines NUMBRINO is contraindicated in patients with a known history of hypersensitivity to cocaine or to the components of the nasal solution. (etiqueta de Cocaína, Advertencias y precauciones)

Inhaled beta agonist : salmeterol ↑ salmeterol Co-administration of salmeterol and PREZISTA/ritonavir is not recommended. (etiqueta de Darunavir, Interacciones medicamentosas)

Inhaled beta agonist: salmeterol ↑ salmeterol Co-administration with salmeterol is not recommended and may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations, and sinus tachycardia. (etiqueta de Darunavir y cobicistat, Interacciones medicamentosas)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (etiqueta de Docetaxel, Advertencias y precauciones)

Avoid concomitant use of other drugs that are also associated with similar cardiac effects (e.g., amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, desipramine, other tricyclic antidepressants). (etiqueta de Dronabinol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Inhaled Beta Agonist: salmeterol ↑ salmeterol Coadministration of salmeterol and GENVOYA is not recommended. (etiqueta de Elvitegravir, cobicistat, emtricitabina y tenofovir, Interacciones medicamentosas)

…(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (etiqueta de Emtricitabina, rilpivirina y tenofovir, Contraindicaciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Etanercept, Advertencia en recuadro)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

The potentiation of sympathomimetic substances and related compounds by MAO inhibitors may result in hypertensive crises (see WARNINGS ). (etiqueta de Fenelzina, Contraindicaciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

…intubation (endotracheal) 1 2 Asthma-related hospitalization (≥24-hour stay) 115 105 ICS = Inhaled Corticosteroid, LABA = Long-acting Beta2-adrenergic Agonist The pediatric safety trial included 6208 pediatric patients 4 to 11 years of age who received ICS/LABA (fluticasone propionate /salmeterol inhalation powder) or ICS (fluticasone propionate inhalation powder). (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Serious Asthma-Related Events – Hospitalizations, Intubations and Death Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death [see Salmeterol Multicenter Asthma Research Trial (SMART) ]. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Inhaled beta-agonist: Salmeterol ↑ Salmeterol Concurrent administration of salmeterol with fosamprenavir calcium is not recommended. (etiqueta de Fosamprenavir, Interacciones medicamentosas)

Avoid the use of preparations, such as decongestants and local anesthetics, that contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines. (etiqueta de Imipramina, Interacciones medicamentosas)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Infliximab, Advertencia en recuadro)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Fluticasone: Coadministration of fluticasone propionate and ketoconazole is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (etiqueta de Ketoconazol, Interacciones medicamentosas)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

• Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . (etiqueta de Liotironina, Advertencia en recuadro)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (etiqueta de Lovastatina, Contraindicaciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. (etiqueta de Mifepristona, Advertencia en recuadro)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (etiqueta de Mitotano, Advertencia en recuadro)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (etiqueta de Moexipril, Advertencias)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

IF INITIATION OF AEROSOLIZED RIBAVIRIN FOR INHALATION SOLUTION, USP TREATMENT APPEARS TO PRODUCE SUDDEN DETERIORATION OF RESPIRATORY FUNCTION, TREATMENT SHOULD BE STOPPED AND REINSTITUTED ONLY WITH EXTREME CAUTION, CONTINUOUS MONITORING AND CONSIDERATION OF CONCOMITANT ADMINISTRATION OF BRONCHODILATORS (SEE WARNINGS ). (etiqueta de Ribavirina, Advertencia en recuadro)

Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (etiqueta de Rilpivirina, Contraindicaciones)

Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (etiqueta de Roflumilast, Advertencias y precauciones)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Serious Asthma-Related Events – Hospitalizations, Intubations and Death Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death [see Salmeterol Multicenter Asthma Research Trial (SMART) ]. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

In a multicenter clinical study, de novo renal transplant patients treated with sirolimus, mycophenolate mofetil (MMF), steroids, and an IL-2 receptor antagonist had significantly higher acute rejection rates and numerically higher death rates compared to patients treated with cyclosporine, MMF, steroids, and IL-2 receptor antagonist. (etiqueta de Sirolimus, Advertencias y precauciones)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (etiqueta de Somatropina, Interacciones medicamentosas)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Tocilizumab, Advertencia en recuadro)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Tofacitinib, Advertencia en recuadro)

Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (etiqueta de Trandolapril, Advertencias)

…(SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) tricyclic antidepressants other antidepressants, such as amoxapine, bupropion, maprotiline, nefazodone, trazodone, vilazodone, vortioxetine amphetamines and methylphenidates medicines that can raise blood pressure (sympathomimetic medicine), such as pseudoephedrine, phenylephrine and ephedrine. (etiqueta de Tranilcipromina, Advertencia en recuadro)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (etiqueta de Tretinoína, Advertencia en recuadro)

If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (etiqueta de Trióxido de arsénico, Advertencia en recuadro)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. (etiqueta de Upadacitinib, Advertencia en recuadro)

Use with additional long-acting beta 2 -agonist: Do not use in combination because of risk of overdose. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

The chance is higher if you are age 60 or older take a blood thinning (anticoagulant) or steroid drug have 3 or more alcoholic drinks every day while using this product have had stomach ulcers or bleeding problems take more or for a longer time than directed take other drugs containing prescription or nonprescription NSAIDs [aspirin, ibuprofen, naproxen, or others]… (etiqueta de Ácido acetilsalicílico, Advertencias)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, anti-platelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs), smoking, use of alcohol, older age, and poor general health status. (etiqueta de Ácido mefenámico, Advertencias y precauciones)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (etiqueta de Ácido zoledrónico, Advertencias y precauciones)

Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (etiqueta de Aclidinio, Interacciones medicamentosas)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (etiqueta de Afatinib, Advertencias y precauciones)

Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (etiqueta de Albendazol, Advertencias y precauciones)

Institute appropriate medical management (e.g., glucocorticoids, epinephrine, meperidine) for infusion-related reactions as needed [see Dosage and Administration (2.2) ] . (etiqueta de Alemtuzumab, Advertencias y precauciones)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (etiqueta de Alendronato, Advertencias y precauciones)

Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (etiqueta de Aliskireno, Advertencias y precauciones)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (etiqueta de Alogliptina y metformina, Interacciones medicamentosas)

If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (etiqueta de Alpelisib, Advertencias y precauciones)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Corticosteroids and Corticotropin (ACTH) Concurrent use of corticosteroids and ACTH may potentiate hypokalemia, which could predispose the patient to cardiac dysfunction. (etiqueta de Anfotericina B, Interacciones medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Albuterol (or other beta 2 agonists): Increase the frequency of monitoring blood pressure and heart rate. (etiqueta de Atomoxetina, Interacciones medicamentosas)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (etiqueta de Aztreonam, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Belladona y opio, Advertencias y precauciones)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (etiqueta de Bendamustina, Advertencias y precauciones)

• Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (etiqueta de Benralizumab, Advertencias y precauciones)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (etiqueta de Bictegravir, emtricitabina y tenofovir alafenamida, Interacciones medicamentosas)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (etiqueta de Bortezomib, Advertencias y precauciones)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Buprenorfina, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Buprenorfina y naloxona, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Butorfanol, Advertencias)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (etiqueta de Cefoxitina, Advertencias y precauciones)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Celecoxib, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (etiqueta de Ciprofloxacino, Advertencias y precauciones)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

These reactions include reversible corneal toxicity, and hemorrhagic conjunctivitis, which may be prevented or diminished by prophylaxis with a local corticosteroid eye drop; cerebral and cerebellar dysfunction, including personality changes, somnolence and coma, usually reversible; severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis… (etiqueta de Citarabina, Advertencias)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etiqueta de Cladribina, Interacciones medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Codeína, Advertencias y precauciones)

Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (etiqueta de Daptomicina, Advertencias y precauciones)

Closely monitor patients for signs of reduced effectiveness when deferasirox is administered with drugs metabolized by CYP3A4 (e.g., alfentanil, aprepitant, budesonide, buspirone, conivaptan, cyclosporine, darifenacin, darunavir, dasatinib, dihydroergotamine, dronedarone, eletriptan, eplerenone, ergotamine, everolimus, felodipine, fentanyl, hormonal contraceptive… (etiqueta de Deferasirox, Interacciones medicamentosas)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (etiqueta de Denosumab, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Sex hormone binding globulins are increased and result in elevated levels of total circulating sex steroids however, free or biologically active levels either decrease or remain unchanged. e. (etiqueta de Desogestrel y etinilestradiol, Precauciones)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

The amount of both steroids should be considered in the choice of an oral contraceptive. (etiqueta de Diacetato de etinodiol y etinilestradiol, Advertencias)

Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (etiqueta de Dicicloverina, Interacciones medicamentosas)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Diclofenaco, Advertencias y precauciones)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Diclofenaco y misoprostol, Advertencias y precauciones)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Diflunisal, Advertencias)

Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (etiqueta de Digoxina, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Drug Interactions Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS, General ). (etiqueta de Doxapram, Interacciones medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (etiqueta de Dupilumab, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (etiqueta de Elexacaftor, tezacaftor e ivacaftor, Advertencias y precauciones)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (etiqueta de Erlotinib, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating corticosteroids and sex steroids, respectively. (etiqueta de Estradiol, Precauciones)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins [see Warnings and Precautions ( 5.11 ) and Drug Interactions ( 7.2 )]. (etiqueta de Estradiol y dienogest, Interacciones medicamentosas)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (etiqueta de Estradiol y noretisterona, Advertencias y precauciones)

Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), SHBG, leading to increased total circulating corticosteroids and sex steroids respectively. (etiqueta de Estrógenos conjugados, Precauciones)

Other binding proteins may be elevated in serum, for example, corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating corticosteroids and sex steroids, respectively. (etiqueta de Estrógenos conjugados y bazedoxifeno, Advertencias y precauciones)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Etodolaco, Advertencias)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (etiqueta de Etravirina, Interacciones medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (etiqueta de Fenilacetato de sodio y benzoato de sodio, Interacciones medicamentosas)

Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (etiqueta de Fenilbutirato de glicerol, Interacciones medicamentosas)

Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (etiqueta de Fenilbutirato de sodio, Interacciones medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Fenoprofeno, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Fentanilo, Advertencias y precauciones)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

In both cases, the patients were taking a 1.25 mg dose of fingolimod (higher than the recommended 0.5 mg dose) and had received high-dose corticosteroid therapy to treat suspected MS relapses. (etiqueta de Fingolimod, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status. (etiqueta de Flurbiprofeno, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (etiqueta de Glimepirida, Interacciones medicamentosas)

…olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. (etiqueta de Glipizida, Interacciones medicamentosas)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (etiqueta de Haloperidol, Interacciones medicamentosas)

Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (etiqueta de Hidralazina, Advertencias)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona e ibuprofeno, Advertencias)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona y homatropina, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidrocodona y paracetamol, Advertencias)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Hidromorfona, Advertencias y precauciones)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (etiqueta de Ibandronato, Advertencias y precauciones)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Ibuprofeno, Advertencias y precauciones)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Ibuprofeno y famotidina, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Indometacina, Advertencias y precauciones)

…Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (etiqueta de Insulina asparta, Interacciones medicamentosas)

…Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (etiqueta de Insulina degludec, Interacciones medicamentosas)

…Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (etiqueta de Insulina detemir, Interacciones medicamentosas)

…Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (etiqueta de Insulina glargina, Interacciones medicamentosas)

…Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (etiqueta de Insulina lispro, Interacciones medicamentosas)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (etiqueta de Ivermectina, Advertencias)

Sympathomimetics and Vasopressin : Sympathomimetics and vasopressin may enhance the sympathomimetic effects of ketamine [see Drug Interactions ( 7.2 )] . (etiqueta de Ketamina, Advertencias y precauciones)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (etiqueta de Ketoprofeno, Advertencias y precauciones)

In addition to past history of ulcer disease, other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Ketorolaco, Advertencias y precauciones)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (etiqueta de Levofloxacino, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Thyroid Hormone Replacement Therapy or Corticosteroid Replacement Therapy Clinical effect Concomitant use of CHCs with thyroid hormone replacement therapy or corticosteroid replacement therapy may increase systemic exposure of thyroid-binding and cortisol-binding globulin [see Warnings and Precautions (5.11) ]. (etiqueta de Levonorgestrel y etinilestradiol, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Levorfanol, Advertencias)

Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone. (etiqueta de Levotiroxina, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (etiqueta de Margetuximab, Advertencias y precauciones)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

MPA Injectable Suspension, USP can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). (etiqueta de Medroxiprogesterona, Advertencias y precauciones)

Laboratory evaluation for adrenal insufficiency and consideration of replacement or stress doses of a rapidly acting glucocorticoid are strongly recommended in such patients. (etiqueta de Megestrol, Advertencias y precauciones)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Meloxicam, Advertencias y precauciones)

Decrease corticosteroids gradually, if appropriate. (etiqueta de Mepolizumab, Advertencias y precauciones)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Metadona, Advertencias y precauciones)

Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (etiqueta de Metazolamida, Interacciones medicamentosas)

If not, corticosteroids may be given and other causes of anemia should be considered. (etiqueta de Metildopa, Advertencias)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. (etiqueta de Metiltestosterona, Advertencias)

This can be corrected by giving appropriate doses of corticosteroids. (etiqueta de Metirapona, Advertencias y precauciones)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

NSAIDs, Aspirin, and Steroids: May elevate and prolong serum methotrexate levels and increase gastrointestinal toxicity. (etiqueta de Metotrexato, Interacciones medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Inhaled corticosteroid may be reduced gradually. (etiqueta de Montelukast, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Morfina, Advertencias y precauciones)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (etiqueta de Moxifloxacino, Advertencias y precauciones)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Nabumetona, Advertencias)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Nalbufina, Advertencias)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Naproxeno, Advertencias y precauciones)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Naproxeno y esomeprazol, Advertencias y precauciones)

In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. (etiqueta de Natalizumab, Advertencias y precauciones)

Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (etiqueta de Nateglinida, Interacciones medicamentosas)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (etiqueta de Nintedanib, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (etiqueta de Ocrelizumab, Advertencias y precauciones)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (etiqueta de Ofloxacino, Advertencias)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Oliceridina, Advertencias y precauciones)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (etiqueta de Omalizumab, Advertencias y precauciones)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Oxaprozina, Advertencias y precauciones)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Oxicodona, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Oxicodona y paracetamol, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Oximorfona, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (etiqueta de Pamidronato, Advertencias y precauciones)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Paracetamol e ibuprofeno, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Paracetamol y codeína, Advertencias)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (etiqueta de Pasireotida, Advertencias y precauciones)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (etiqueta de Penicilamina, Advertencias)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Pentazocina y naloxona, Advertencias)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Petidina (meperidina), Advertencias y precauciones)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

…medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are… (etiqueta de Pioglitazona y glimepirida, Interacciones medicamentosas)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Piroxicam, Advertencias y precauciones)

Prior and Concomitant Treatment with Anti-neoplastic, Immune-Modulating, or Immunosuppressive Therapies Anti-neoplastic, immune-modulating, or immunosuppressive therapies (including corticosteroids) should be coadministered with caution because of the risk of additive immune system effects [see Drug Interactions (7.1) ] . (etiqueta de Ponesimod, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with budesonide and formoterol fumarate dihydrate. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (etiqueta de Propofol, Advertencias y precauciones)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

…Calcium Channel Blockers Diltiazem Decrease exposure Nifedipine Rifampin 1200 mg administered as a single oral dose 8 hours before administering a single oral dose of nifedipine 10 mg Decrease exposure Verapamil Decrease exposure Corticosteroids Numerous cases in the literature describe a decrease in glucocorticoid effect when used concomitantly with rifampin. (etiqueta de Rifampicina, Interacciones medicamentosas)

…Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants… (etiqueta de Rifapentina, Interacciones medicamentosas)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etiqueta de Risedronato, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (etiqueta de Rocuronio, Advertencias y precauciones)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Salsalato, Advertencias)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Sulindaco, Advertencias)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (etiqueta de Sumatriptán y naproxeno, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (etiqueta de Suxametonio (succinilcolina), Interacciones medicamentosas)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Tapentadol, Advertencias y precauciones)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (etiqueta de Temozolomida, Advertencias y precauciones)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (etiqueta de Temsirolimus, Advertencias y precauciones)

Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (etiqueta de Teofilina, Advertencias)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (etiqueta de Teriparatida, Advertencias y precauciones)

Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (etiqueta de Tesamorelina, Interacciones medicamentosas)

Abuse of Testosterone and Monitoring of Serum Testosterone : If testosterone use at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids is suspected, check serum testosterone concentration ( 5.5 ). (etiqueta de Testosterona, Advertencias y precauciones)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Beta-blockers: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (etiqueta de Tiotropio, Interacciones medicamentosas)

Drugs That Increase Catecholamines: Tolcapone did not influence the effect of ephedrine, an indirect sympathomimetic, on hemodynamic parameters or plasma catecholamine levels, either at rest or during exercise. (etiqueta de Tolcapona, Interacciones medicamentosas)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (etiqueta de Tolmetina, Advertencias)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Tramadol, Advertencias y precauciones)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (etiqueta de Tramadol y paracetamol, Advertencias y precauciones)

Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (etiqueta de Trastuzumab, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Diuretics: Use with caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir): Risk of increased systemic corticosteroid effects. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. (etiqueta de Budesonida y formoterol, Interacciones medicamentosas)

More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids) [ see Boxed Warning ]. (etiqueta de Warfarina, Interacciones medicamentosas)

If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (etiqueta de Zanamivir, Advertencias y precauciones)

Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (etiqueta de Zenocutuzumab, Advertencias y precauciones)

Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (etiqueta de Acarbosa, Interacciones medicamentosas)

Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (etiqueta de Ácido bempedoico, Advertencias y precauciones)

If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (etiqueta de Alteplasa, Advertencias y precauciones)

Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (etiqueta de Amikacina, Advertencias y precauciones)

If paradoxical bronchospasm occurs following dosing with budesonide and formoterol fumarate dihydrate, it should be treated immediately with an inhaled, short-acting bronchodilator, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL should be discontinued immediately, and alternative therapy should be instituted. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (etiqueta de Ampicilina, Advertencias)

Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (etiqueta de Bevacizumab, Advertencias y precauciones)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etiqueta de Bromocriptina, Interacciones medicamentosas)

The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (etiqueta de Busulfano, Advertencias)

Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (etiqueta de Calcitriol, Interacciones medicamentosas)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefaclor, Advertencias)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefadroxilo, Advertencias y precauciones)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefdinir, Advertencias)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefotetán, Advertencias)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Cefprozilo, Advertencias)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (etiqueta de Ceftazidima, Advertencias)

Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (etiqueta de Ceftriaxona, Advertencias y precauciones)

The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (etiqueta de Clofarabina, Advertencias y precauciones)

Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (etiqueta de Clomifeno, Advertencias)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with budesonide and formoterol fumarate dihydrate continues, but at times therapy with budesonide and formoterol fumarate dihydrate may need to be interrupted. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (etiqueta de Corticotropina, Advertencias y precauciones)

These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Dapagliflozina y metformina, Interacciones medicamentosas)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (etiqueta de Dasatinib, Advertencias y precauciones)

These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (etiqueta de Droperidol, Interacciones medicamentosas)

Steroid hormones may be poorly metabolized in patients with impaired liver function. (etiqueta de Drospirenona y etinilestradiol, Advertencias y precauciones)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with budesonide and formoterol fumarate dihydrate continues, but at times therapy with budesonide and formoterol fumarate dihydrate may need to be interrupted. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Empagliflozina y metformina, Interacciones medicamentosas)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (etiqueta de Etonogestrel y etinilestradiol, Interacciones medicamentosas)

Steroids may or may not be effective in controlling these hemolytic episodes. (etiqueta de Fludarabina, Advertencias y precauciones)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Glibenclamida, Interacciones medicamentosas)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (etiqueta de Glibenclamida y metformina, Interacciones medicamentosas)

These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Glipizida y metformina, Precauciones)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (etiqueta de Glucagón, Advertencias y precauciones)

TREMFYA was subsequently discontinued, and the liver test abnormalities resolved following administration of corticosteroids [see Adverse Reactions (6.1) ] . (etiqueta de Guselkumab, Advertencias y precauciones)

In a study of patients with asthma whose bronchodilators were temporarily withheld for assessment, bronchoconstriction and wheezing following AFREZZA dosing was reported in 29% (5/17) and 0% (0/13) of patients with and without a diagnosis of asthma, respectively. (etiqueta de Insulina regular (humana), Advertencias y precauciones)

If paradoxical bronchospasm occurs following dosing with budesonide and formoterol fumarate dihydrate, it should be treated immediately with an inhaled, short-acting bronchodilator, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL should be discontinued immediately, and alternative therapy should be instituted. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (etiqueta de Lenalidomida, Advertencias y precauciones)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Linagliptina y metformina, Interacciones medicamentosas)

The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (etiqueta de Melfalán, Advertencias)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (etiqueta de Metformina, Interacciones medicamentosas)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (etiqueta de Metimazol, Advertencias)

Intra-arterial glucocorticoid injection at the site of injury, followed by systemic steroids. (etiqueta de Metohexital, Advertencias)

When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with budesonide and formoterol fumarate dihydrate continues, but at times therapy with budesonide and formoterol fumarate dihydrate may need to be interrupted. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (etiqueta de Mitoxantrona, Interacciones medicamentosas)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (etiqueta de Naltrexona, Advertencias y precauciones)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (etiqueta de Norelgestromina y etinilestradiol, Interacciones medicamentosas)

Steroid hormones may be poorly metabolized in patients with impaired liver function. (etiqueta de Noretisterona y etinilestradiol, Advertencias y precauciones)

Interactions with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (etiqueta de Norgestimato y etinilestradiol, Interacciones medicamentosas)

Interference with Laboratory Tests The use of contraceptive steroids may influence the results of certain laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. (etiqueta de Norgestrel y etinilestradiol, Precauciones)

If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (etiqueta de Oxacilina, Advertencias)

Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (etiqueta de Penicilina G, Advertencias)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (etiqueta de Penicilina V, Advertencias)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (etiqueta de Pioglitazona y metformina, Interacciones medicamentosas)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (etiqueta de Propiltiouracilo, Advertencias)

Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (etiqueta de Quinina, Interacciones medicamentosas)

Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Raloxifeno, Interacciones medicamentosas)

…antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (etiqueta de Repaglinida, Interacciones medicamentosas)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (etiqueta de Rituximab, Advertencias y precauciones)

These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etiqueta de Saxagliptina y metformina, Interacciones medicamentosas)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (etiqueta de Sitagliptina y metformina, Interacciones medicamentosas)

If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (etiqueta de Tenecteplasa, Advertencias y precauciones)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etiqueta de Tobramicina, Interacciones medicamentosas)

If paradoxical bronchospasm occurs following dosing with budesonide and formoterol fumarate dihydrate, it should be treated immediately with an inhaled, short-acting bronchodilator, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL should be discontinued immediately, and alternative therapy should be instituted. (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. (etiqueta de Ustekinumab, Advertencias y precauciones)

Los corticosteroides como la prednisona reducen la absorción de calcio y alteran el metabolismo de la vitamina D, lo que contribuye a la pérdida de masa ósea. (NIH Office of Dietary Supplements, Vitamin D)

An open-label, nonrandomized clinical study examined the immune responsiveness to varicella vaccine in 243 asthma patients 12 months to 8 years of age who were treated with budesonide inhalation suspension 0.25 mg to 1 mg daily (n=151) or noncorticosteroid asthma therapy (n=92) (i.e., beta 2 -agonists, leukotriene receptor antagonists, cromones). (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

An open-label, nonrandomized clinical study examined the immune responsiveness to varicella vaccine in 243 asthma patients 12 months to 8 years of age who were treated with budesonide inhalation suspension 0.25 mg to 1 mg daily (n=151) or noncorticosteroid asthma therapy (n=92) (i.e., beta 2 -agonists, leukotriene receptor antagonists, cromones). (etiqueta de Budesonida y formoterol, Advertencias y precauciones)

Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (etiqueta de Ziprasidona, Advertencias y precauciones)